Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Catheter-Related Infections | 3 | 2019 | 381 | 0.99 | Why? |
| Urinary Tract Infections | 2 | 2017 | 534 | 0.84 | Why? |
| Xenon | 2 | 2020 | 27 | 0.83 | Why? |
| Cerebral Ventriculitis | 1 | 2017 | 10 | 0.73 | Why? |
| Cross Infection | 6 | 2018 | 8675 | 0.65 | Why? |
| Leprosy | 1 | 2019 | 142 | 0.64 | Why? |
| Ethics, Research | 1 | 2020 | 328 | 0.63 | Why? |
| Meningitis | 1 | 2017 | 163 | 0.61 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.56 | Why? |
| Clostridium Infections | 2 | 2018 | 595 | 0.54 | Why? |
| Staphylococcal Infections | 3 | 2018 | 1099 | 0.52 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.50 | Why? |
| Ultraviolet Rays | 2 | 2020 | 1272 | 0.49 | Why? |
| Intensive Care Units | 8 | 2020 | 29594 | 0.46 | Why? |
| Encephalitis | 1 | 2017 | 797 | 0.40 | Why? |
| Disease Transmission, Infectious | 4 | 2021 | 9044 | 0.38 | Why? |
| Disinfection | 2 | 2020 | 2912 | 0.37 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.33 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.30 | Why? |
| Neurosurgical Procedures | 1 | 2017 | 1738 | 0.30 | Why? |
| Whooping Cough | 1 | 2007 | 201 | 0.27 | Why? |
| Communicable Diseases | 1 | 2019 | 2148 | 0.26 | Why? |
| Minnesota | 4 | 2020 | 509 | 0.26 | Why? |
| Dermatology | 1 | 2019 | 1999 | 0.25 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.24 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.24 | Why? |
| Vaccines | 1 | 2019 | 3692 | 0.20 | Why? |
| Midwestern United States | 1 | 2018 | 109 | 0.19 | Why? |
| Housekeeping, Hospital | 1 | 2018 | 37 | 0.19 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.19 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 220 | 0.18 | Why? |
| Staphylococcal Protein A | 1 | 2017 | 32 | 0.18 | Why? |
| Security Measures | 1 | 2020 | 211 | 0.17 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.17 | Why? |
| Molecular Typing | 1 | 2018 | 280 | 0.17 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2014 | 12361 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.15 | Why? |
| Pneumonia | 1 | 2015 | 5652 | 0.14 | Why? |
| Catheterization, Central Venous | 1 | 2019 | 458 | 0.13 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.13 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.13 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.12 | Why? |
| Humans | 30 | 2021 | 930598 | 0.12 | Why? |
| Drug Industry | 1 | 2020 | 689 | 0.12 | Why? |
| Disease Outbreaks | 3 | 2018 | 27595 | 0.12 | Why? |
| Pulmonary Artery | 1 | 2019 | 803 | 0.12 | Why? |
| Immunization Schedule | 1 | 2019 | 1305 | 0.11 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.11 | Why? |
| Physician-Patient Relations | 1 | 2021 | 1266 | 0.11 | Why? |
| Anti-Infective Agents, Local | 1 | 2017 | 520 | 0.11 | Why? |
| Travel | 3 | 2019 | 7220 | 0.10 | Why? |
| Hospital Units | 1 | 2017 | 1017 | 0.10 | Why? |
| Staphylococcus aureus | 1 | 2017 | 844 | 0.10 | Why? |
| Hospitals, Teaching | 1 | 2018 | 1609 | 0.10 | Why? |
| Health Personnel | 5 | 2021 | 29646 | 0.10 | Why? |
| Middle East | 1 | 2014 | 1418 | 0.10 | Why? |
| Heart Transplantation | 1 | 2019 | 1293 | 0.09 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.09 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.09 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.09 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.08 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.08 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.08 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.08 | Why? |
| United States | 5 | 2021 | 46150 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.08 | Why? |
| Adult | 8 | 2021 | 244371 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.07 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Macrolides | 1 | 2007 | 369 | 0.06 | Why? |
| Saudi Arabia | 1 | 2014 | 4423 | 0.06 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Child | 4 | 2020 | 70012 | 0.06 | Why? |
| Practice Patterns, Physicians' | 1 | 2021 | 4927 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.06 | Why? |
| Complement C4b | 1 | 2021 | 57 | 0.06 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.06 | Why? |
| Kidney Transplantation | 1 | 2021 | 5397 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Staining and Labeling | 1 | 2021 | 169 | 0.05 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Databases, Factual | 1 | 2015 | 6248 | 0.05 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.05 | Why? |
| Capillaries | 1 | 2021 | 257 | 0.05 | Why? |
| Universal Precautions | 1 | 2020 | 293 | 0.05 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| Allografts | 1 | 2021 | 761 | 0.04 | Why? |
| Choice Behavior | 1 | 2021 | 319 | 0.04 | Why? |
| Tertiary Care Centers | 1 | 2015 | 8248 | 0.04 | Why? |
| Transplantation Conditioning | 1 | 2019 | 323 | 0.04 | Why? |
| Virology | 1 | 2020 | 489 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Forecasting | 2 | 2021 | 4492 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Male | 9 | 2021 | 367725 | 0.04 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.04 | Why? |
| Spatio-Temporal Analysis | 1 | 2021 | 1182 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2017 | 446 | 0.03 | Why? |
| Risk Reduction Behavior | 1 | 2020 | 946 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Nasal Cavity | 1 | 2018 | 909 | 0.03 | Why? |
| Equipment Reuse | 1 | 2020 | 985 | 0.03 | Why? |
| Intensive Care Units, Neonatal | 1 | 2018 | 749 | 0.03 | Why? |
| Biopsy | 1 | 2021 | 2811 | 0.03 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.03 | Why? |
| Infant | 2 | 2020 | 30274 | 0.03 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Graft Rejection | 1 | 2021 | 1766 | 0.03 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.03 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
| Female | 7 | 2021 | 380317 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Hand Hygiene | 1 | 2018 | 1493 | 0.02 | Why? |
| Aged | 4 | 2020 | 215776 | 0.02 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.02 | Why? |
| Coronavirus | 1 | 2014 | 18339 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2015 | 88759 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Young Adult | 1 | 2015 | 93724 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Transplant Recipients | 1 | 2019 | 4982 | 0.02 | Why? |
| Animals | 2 | 2020 | 78931 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| China | 1 | 2003 | 50654 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Risk Factors | 1 | 2019 | 71621 | 0.01 | Why? |
Sampathkumar's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(155)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(185)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_